Showing results (231-240 of 308) with videos related to
Sort By:
Pageof 31
European Journal of Pharmacology|September 24, 2004
Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trialVictor L Serebruany, Alex I Malinin, David C Sane, et al.Journal of Clinical Psychopharmacology|April 25, 2006
Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humansDan Atar, Alex Malinin, Aviv Takserman, et al.European Journal of Heart Failure|August 10, 2000
Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapyV L Serebruany, S R Murugesan, A Pothula, et al.Cardiology|May 5, 2016
Asymptomatic Pulmonary Embolism after AblationGamze Babur Guler, Mehmet Mustafa Can, Ekrem Guler, et al.Cardiology|June 26, 2001
Platelet function and fibrinolytic agents: two sides of a coin?K P Callahan, A I Malinin, P A Gurbel, et al.Journal of Thrombosis and Thrombolysis|March 23, 2000
Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarctionV L Serebruany, D R Lowry, S Y Fuzailov, et al.The American Journal of Cardiology|September 25, 1999
Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitorsG V Nair, P A Gurbel, C M O'Connor, et al.American Heart Journal|September 10, 2010
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysisDániel Aradi, András Komócsi, András Vorobcsuk, et al.Journal of Cardiovascular Pharmacology|January 1, 1997
Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expressionV L Serebruany, J V Ordonez, W R Herzog, et al.Circulation|August 20, 2003
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trialJacqueline Saw, Steven R Steinhubl, Peter B Berger, et al.Pageof 31